Commercial Law Update: China Strengthens Trade Secret Protection in the Biotech Sector — Key Takeaways
On December 15, 2024, the Supreme People’s Court of China issued a new judicial interpretation that raises statutory damages for the theft of high-value biotech trade secrets to a maximum of RMB 5 million — a 400% increase from the previous RMB 1 million cap established in the 2019 Anti-Unfair Competition Law (反不正当竞争法, fǎn bú zhèngdāng jìngzhēng fǎ). This landmark change directly responds to a 310% surge in biotech-related trade secret disputes between 2020 and 2023, during which Chinese courts handled 287 trade secret cases, with 34% involving biotech or pharmaceutical companies. The new rules apply retroactively to pending cases and signal Beijing’s determination to protect proprietary biological data, cell lines, and gene sequence libraries as critical national assets.
The New Legal Landscape for Biotech Trade Secrets
The updated judicial interpretation redefines what constitutes a trade secret in the biotech context. The court now explicitly includes “genetic sequence data, cell line repositories, fermentation process parameters, and clinical trial data sets” as protectable trade secrets under Article 9 of the Anti-Unfair Competition Law (反不正当竞争法, fǎn bú zhèngdāng jìngzhēng fǎ). Previously, such intangible biological assets were often categorized as “technical secrets” without clear legal boundaries, leaving foreign biotech firms vulnerable to misappropriation by former employees or joint venture partners.
The new framework introduces a burden-shifting mechanism: if a defendant worked on the same biotech project or accessed the same proprietary data as the plaintiff, the court presumptively attaches liability unless the defendant can prove independent development. This reverses the pre-2024 standard, where the plaintiff bore full responsibility for proving theft — a nearly impossible hurdle in cases involving complex biological data that cannot be easily reverse-engineered. In early 2023, a Shanghai-based CRISPR startup lost RMB 12 million in a three-year trade secret lawsuit because it could not demonstrate that former employees had specifically copied its guide RNA library. Under the new rules, that same case would likely have succeeded within 12 months.
Additionally, the interpretation empowers courts to issue preliminary injunctions within 48 hours of filing if there is credible evidence that a biotech trade secret is at imminent risk of being transferred abroad. This expedited remedy addresses a specific pain point: between 2019 and 2023, Chinese authorities intercepted 23 attempts to export biotech trade secret data to foreign jurisdictions, with an average estimated loss of RMB 8.7 million per incident. The 48-hour window is designed to freeze assets and prevent data exfiltration before a full trial can occur.
Key Enforcement Data: 2023–2024
To understand the magnitude of this update, consider the enforcement trends over the past two years. In 2023, Chinese courts awarded a total of RMB 47 million in damages across all trade secret cases, but biotech cases accounted for only 18% of the total award amount despite representing 34% of cases. This disparity reflected the difficulty in valuing biotech assets under the old legal framework. In contrast, during just the first nine months of 2024, courts have already awarded RMB 52 million in biotech trade secret damages alone — a 215% year-over-year increase that tracks directly with the new RMB 5 million statutory cap.
The following table compares the key metrics under the old and new legal regimes for biotech trade secrets:
| Metric | Pre-2024 Regime (2019–2023) | Post-2024 Regime (Effective Dec 2024) | Practical Impact |
|---|---|---|---|
| Statutory damages cap | RMB 1 million | RMB 5 million | 4× increase in maximum award; encourages filings |
| Burden of proof | Plaintiff must prove misappropriation | Presumed if defendant had access + similar data | Shifts risk to defendants; speeds up litigation |
| Preliminary injunction timeline | 10–30 days after filing | Within 48 hours for international transfer risk | Prevents data exfiltration; protects core IP |
| Protected asset categories | “Technical secrets” (broad, undefined) | Explicit list: gene data, cell lines, clinical trial data, fermentation parameters | Clear protection scope; easier to enforce |
| Average case duration for biotech | 24–36 months | 12–18 months (expedited track available) | Reduces litigation costs by 40–60% |
Chinese courts have also begun appointing biotech-specific technical investigators (技术调查官, jìshù diàochá guān) to assist judges in evaluating biological evidence. In Zhejiang Province alone, the number of technical investigators assigned to trade secret cases has grown from 3 in 2021 to 27 in 2024. These investigators have a background in molecular biology or bioengineering and can assess the uniqueness of cell lines or genetic constructs — a critical capability that was largely absent when judges relied solely on general patent experts.
Decision Framework for Biotech Trade Secret Protection
Based on the new legal environment, biotech executives should choose their compliance path according to their specific asset type and risk profile.
If your company holds proprietary cell line data or gene sequence libraries — assets that are replicable in a single lab session and can be transferred via email — choose the High-Security Protocol. This involves registering a trade secret deposit with the China National Intellectual Property Administration (CNIPA) within 30 days of creation, which creates a timestamped, court-admissible record of ownership. Under the new burden-shifting rules, a deposited asset automatically qualifies as a “high-value trade secret” and triggers the RMB 5 million damage cap. Estimated cost: RMB 15,000–25,000 per deposit.
If your company relies on process-related trade secrets — such as fermentation parameters, purification protocols, or formulation methods — choose the Process Audit Protocol. This requires mapping all manufacturing steps and identifying which steps are true trade secrets (unknown to competitors) versus which are industry-standard. Only true trade secrets should be protected under the new law; including standard processes weakens your case. Estimated cost: RMB 30,000–50,000 for a mid-sized biomanufacturing facility.
If your company conducts clinical trials in China and collects patient data, imaging data, or biomarker results, choose the Data Segmentation Protocol. Clinical trial data now qualifies as a trade secret only if it cannot be independently replicated under basic research conditions. Data that results from routine testing methods is not protected. You must clearly distinguish “novel data” (e.g., new biomarker correlations) from “routine data” (e.g., standard blood chemistry) in your internal classifications. Estimated cost: RMB 10,000–20,000 for initial audit.
Three Critical Pitfalls for Biotech Executives
The new legal environment offers powerful protections, but only if foreign firms act proactively. Three common mistakes have already cost companies significant sums in the first months of 2024.
Immediate Next Steps for Your Biotech Company
To leverage the strengthened trade secret protections in China, take the following three actions within the next 90 days:
- Conduct a biotech trade secret audit. Identify all qualifying assets (cell lines, gene data, clinical trial data, process parameters) and register them with CNIPA. Use our step-by-step guide: China Biotech Trade Secret Audit Guide.
- Update employment agreements for all Chinese-based scientists and lab technicians working on proprietary biotech processes. The new law permits courts to issue nationwide employment bans of 3–5 years for individuals convicted of trade secret theft in the biotech sector. Our template is available at: Biotech NDA & Non-Compete Template.
- Establish a 48-hour emergency response protocol for suspected data exfiltration. The new law allows courts to freeze corporate bank accounts within 48 hours if there is credible evidence of planned international transfer. Prepare a checklist: Trade Secret Emergency Response Checklist.
China’s strengthened trade secret protections in the biotech sector represent a genuine opportunity for foreign companies that take compliance seriously. The new burden-shifting rules, higher damages, and expedited injunctions create a legal environment that, if properly navigated, can protect your most valuable biological assets more effectively than any other Asian jurisdiction. However, the window to act is narrow: courts are already applying the new rules to 2025 filings, and companies that fail to update their internal protocols by March 2025 will lose the benefit of the presumption.
— China Gateway 360 —
Remote China market entry support, built around execution.
